Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules f… Read more
Ono Pharmaceutical Co. Ltd (OPHLF) - Total Assets
Latest total assets as of December 2025: $1.09 Trillion USD
Based on the latest financial reports, Ono Pharmaceutical Co. Ltd (OPHLF) holds total assets worth $1.09 Trillion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ono Pharmaceutical Co. Ltd - Total Assets Trend (2005–2025)
This chart illustrates how Ono Pharmaceutical Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ono Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
Ono Pharmaceutical Co. Ltd's total assets of $1.09 Trillion consist of 42.8% current assets and 57.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.2% |
| Accounts Receivable | $135.02 Billion | 12.7% |
| Inventory | $74.86 Billion | 7.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $330.04 Billion | 31.0% |
| Goodwill | $21.19 Billion | 2.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Ono Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ono Pharmaceutical Co. Ltd's current assets represent 42.8% of total assets in 2025, an increase from 40.9% in 2005.
- Cash Position: Cash and equivalents constituted 19.2% of total assets in 2025, up from 3.5% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 32.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 31.0% of total assets.
Ono Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of Ono Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Ono Pharmaceutical Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Ono Pharmaceutical Co. Ltd generates 0.46x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Ono Pharmaceutical Co. Ltd generates $ 4.70 in net profit.
Ono Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.02 | 3.55 | 2.64 |
| Quick Ratio | 2.56 | 2.91 | 2.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $290.26 Billion | $ 310.09 Billion | $ 153.91 Billion |
Ono Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Ono Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.58 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 16.5% |
| Total Assets | $1.06 Trillion |
| Market Capitalization | $4.26 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Ono Pharmaceutical Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Ono Pharmaceutical Co. Ltd's assets grew by 16.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ono Pharmaceutical Co. Ltd (2005–2025)
The table below shows the annual total assets of Ono Pharmaceutical Co. Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $1.06 Trillion | +16.46% |
| 2024-03-31 | $913.67 Billion | +3.54% |
| 2023-03-31 | $882.44 Billion | +19.38% |
| 2022-03-31 | $739.20 Billion | -1.02% |
| 2021-03-31 | $746.84 Billion | +10.90% |
| 2020-03-31 | $673.44 Billion | +2.81% |
| 2019-03-31 | $655.06 Billion | +7.52% |
| 2018-03-31 | $609.23 Billion | -1.33% |
| 2017-03-31 | $617.46 Billion | +14.25% |
| 2016-03-31 | $540.45 Billion | +3.02% |
| 2015-03-31 | $524.59 Billion | +7.95% |
| 2014-03-31 | $485.96 Billion | +6.67% |
| 2013-03-31 | $455.57 Billion | +4.39% |
| 2012-03-31 | $436.41 Billion | +2.82% |
| 2011-03-31 | $424.44 Billion | -2.03% |
| 2010-03-31 | $433.23 Billion | +2.84% |
| 2009-03-31 | $421.28 Billion | -11.74% |
| 2008-03-31 | $477.34 Billion | -5.44% |
| 2007-03-31 | $504.81 Billion | +0.07% |
| 2006-03-31 | $504.45 Billion | +14.84% |
| 2005-03-31 | $439.27 Billion | -- |